Fujifilm Biotech CEO warns CDMOs must expand services ahead of looming patent cliff
Fujifilm Biotechnologies CEO Lars Petersen said drugmakers are gearing up for a looming biopharma patent cliff in 2026, a situation that could pressure revenue streams as key patents expire.
He warned that contract development and manufacturing organizations need to broaden their service offerings to remain competitive as the industry shifts.
Petersen noted that the current year has already seen a surge in dealmaking as companies look for partnerships to mitigate the impact of the patent cliff.
The comments highlight the strategic adjustments CDMOs may need to make to support drugmakers navigating the upcoming challenges.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “The patent cliff is looming and CDMOs need to be prepared, Fujifilm CEO says”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that